This patent takes advantage of the fact that early hematopoietic stem cells are usually CD34+ and quiescent. By treatment of CD34+ cells with cytotoxic agents that kill proliferating cells, a population of primitive stem cells may be obtained.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.